Drugs / Octreotide LAR
Octreotide LAR
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01886287 | Dec 2013 → Aug 2014 | neuroendocrine carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01567488 | Jun 2011 → Sep 2014 | digestive system neuroendocrine neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06784752 | May 2025 → Dec 2028 expected | digestive system neuroendocrine neoplasm | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT01578239 | Sep 2012 → Jul 2015 | intestinal neuroendocrine neoplasm | Advanced Accelerator Applications | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT00108355 | Dec 2003 → Aug 2010 | cirrhosis of liver | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00461149 | Jan 1995 → Dec 2006 | acromegaly | Federico II University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01157858 Comparator | Jun 2010 → Jul 2012 | liver disorder | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01538966 Comparator | Mar 2012 → May 2022 | acromegaly | Cedars-Sinai Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | octreotide LAR | “primary octreotide LAR, lanreotide SR, or sc octreotide therapy” PMID 15886238 ↗ May 2005 |
| Known as | OCLAR | “Individually tailored octreotide LAR (OCLAR) was administered.” PMID 16449332 ↗ Jan 2006 |
| Known as | OCT-LAR | “the slow-release form of octreotide (OCT; Sandostatin LAR, OCT-LAR), for im injection every 28 days” PMID 10999798 ↗ Sep 2000 |
| Known as | octreotide-long-acting repeatable | “Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients” PMID 12843148 ↗ Jul 2003 |
| Known as | Sandostatin LAR | “the slow-release form of octreotide (OCT; Sandostatin LAR, OCT-LAR), for im injection every 28 days” PMID 10999798 ↗ Sep 2000 |
| Action | Inhibit | “the inhibitory effect of octreotide on the IGF-I (insulin like growth factor 1) system preventing the activation of the mTOR system by this factor” NCT01567488 ↗ |
| Modality | Other / unclassified | “The results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (SRLs), octreotide and lanreotide, have supported the use of these agents” PMID 15827109 ↗ Apr 2005 |
| Route | Intramuscular | “Octreotide LAR 20 mg intramuscular injection every 30 days” NCT00108355 ↗ |